News | September 02, 2022
Ashland to expand bioresorbable polymers capacity in Ireland
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Subscribe To Our Newsletter & Stay Updated
